Browse studies

Find your next paid study

42 recruiting studies matching your filters

A Multi-Center, Open Label, Phase 1/2 Study of CP-383, in Patients With Advanced or Metastatic Solid Tumors

The goal of this clinical trial is to learn if an investigational drug CP-383 works to treat advanced cancer. It will also learn about the safety of CP-383. Th…

Solid Tumor MalignanciesColorectal CarcinomaSmall Cell Lung Cancer ( SCLC )+4 more

Estimated

~$10 – $8,750

Tasca TherapeuticsNCT07030257

Tumor-informed ctDNA Testing for Minimal Residual Disease Monitoring Following Curative-intent Treatment of Squamous Cell Carcinoma of the Head and Neck.

This is a single-center, non-interventional, observational study that evaluates the correlation of circulating tumor DNA (ctDNA) testing to cancer relapse for …

Squamous Cell Carcinoma of Head and NeckSquamous Cell Carcinoma Head and Neck Cancer (HNSCC)Squamous Cell Carcinoma of Skin+1 more

Estimated

~$10 – $675

University of California, San FranciscoNCT06606028

Phase 1

A Phase 1a/1b, First-in-Human, Open-Label, Multi-Center, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LB-LR1109, When Administered Alone for the Treatment of Advanced or Metastatic Solid Tumors, and in Combination With Atezolizumab for the Treatment of Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

This is a Phase 1a/1b, first-in-human (FIH), multi-center, open-label, non-randomized, dose escalation study, designed to determine the Maximum tolerated dose(…

Non-small Cell Lung Cancer(NSCLC)Head and Neck Squamous Cell Carcinoma(HNSCC)Renal Cell Carcinoma(RCC)+2 more

Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable Squamous Cell Carcinoma of the Head and Neck: a Phase 2 Trial

This trial is to evaluate the safety and efficacy of ficerafusp alfa in combination with pembrolizumab prior to surgical resection in participants with resecta…

Head and Neck Squamous Cell Carcinoma (HNSCC)Squamous Cell Carcinoma of the Head and Neck

Estimated

~$10 – $7,500

Dana-Farber Cancer InstituteNCT07465276

Phase 1

Phase 1/2 Open Label, Safety and Preliminary Efficacy Study of a Live Biotherapeutic Product (CJRB-101) in Combination With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer

Study CJB-101-01 will be conducted at multiple centers in the USA and Republic of Korea as an open-label safety and preliminary efficacy study of CJRB-101 in c…

NSCLCHNSCCMelanoma+3 more

Estimated

~$10 – $8,750

CJ Bioscience, Inc.NCT05877430

Observational

High-resolution Specimen PET-CT Imaging for the Intraoperative Visualization of Resection Margins: an Exploratory Study

Imaging will be exploratory and be used intraoperatively. There have been no discovered risks associated with the device to be used in this study, and none are…

CancerSolid Malignant TumorsSCC - Squamous Cell Carcinoma+2 more

Estimated

~$10 – $6,250

Vanderbilt-Ingram Cancer CenterNCT06915454